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Abstract: Transforming rearrangements of the ALK (anaplastic
lymphoma kinase) gene have recently been described in non-small
cell lung cancer (NSCLC). The most common rearrangement arises
from an inversion in the short arm of chromosome 2 that creates a
fusion between the 5 portion of the EML4 (echinoderm microtu-
bule-associated protein-like 4) gene and the 3 portion of the ALK
gene. At least seven ALK gene rearrangement variants have been
described involving different EML4-ALK breakpoints or rarely other
non-EML4 fusion partners. ALK rearrangements may be readily
identified in tumor tissue by reverse transcription-polymerase chain
reaction or fluorescent in situ hybridization. Although ALK gene
rearrangements affect only about 4% of all lung cancers, they are
more frequent in adenocarcinomas, in never or light smokers, and
seem almost mutually exclusive with activating EGFR or KRAS
mutations. Promising results seen in patients with NSCLC contain-
ing fluorescent in situ hybridization-detected ALK rearrangements
treated on a phase I study with PF02341066, an oral ALK inhibitor,
indicate that ALK represents a new therapeutic target in this molec-
ularly defined subset of NSCLC.
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Although chromosomal translocations are the most com-mon genetic change in cancer genomes1 and are fre-
quently described in hematologic malignancies, they have
only recently been documented in epithelial malignancies
such as non-small cell lung cancer (NSCLC)2 and prostate
cancer.3 In 2007, EML4-ALK, a novel fusion gene arising as
a result of an inversion in chromosome 2 that juxtaposed the
5 end of the EML4 gene with the 3 end of the ALK gene,
was reported in a subset of patients with NSCLC. This gene
arrangement was shown to be transforming both in vitro and
in vivo. Since then, several variant ALK gene rearrangements
have been identified, and the clinical/pathologic features
associated with “ALK-positive” NSCLC have been described.
Recently, evidence that the fusion proteins resulting from
ALK gene rearrangements constitute a bona fide therapeutic
target has been provided in a phase I trial of a specific ALK
inhibitor in known ALK-positive NSCLC.
IDENTIFICATION OF EML4-ALK IN NSCLC
In 1997, Soda et al.2 screened a cDNA library derived
from the tumor of a 62-year-old Japanese male smoker with
adenocarcinoma of the lung for transforming activity. One of
the cDNAs with transforming activity was found to code for
a novel fusion gene arising from an inversion on the short arm
of chromosome 2 [Inv(2)(p21p23)] that joined exons 1–13 of
EML4 to exons 20–29 of ALK.2 The resulting chimeric
protein, EML4-ALK, contained an N-terminus derived from
EML4 fused to the C-terminal kinase domain of ALK, which
permitted ligand-independent dimerization and constitutive
activation of ALK. In addition to its transforming ability in
3T3 cell lines and xenografts, lung-specific expression of
EML4-ALK in transgenic mice resulted in multiple lung
adenocarcinomas.4 Significantly, treatment with an ALK in-
hibitor was able to cause regression of tumors.2,4
Multiple variants of EML4-ALK have since been
reported.2,5–9 All variants encode the same cytoplasmic por-
tion of ALK but contain different truncations of EML4 (at
exons 2, 6, 13, 14, 15, 18, and 20), and those tested to date
have all demonstrated biologic gain of function (reviewed by
Horn and Pao10). Other rare fusion partners for ALK have also
been described, including TRK-fused gene TFG11 and
KIF5B.8
STRUCTURE AND FUNCTION OF ALK
AND EML4
EML4 and ALK are closely located genes situated on
the short arm of chromosome 2 (2p21 and 2p23, respectively)
where they are separated by a distance of 12.7 megabases and
are oriented in opposite directions.
Full-length ALK was cloned in 199712,13 and is a mem-
ber of the insulin receptor family of receptor tyrosine kinases,
of which leukocyte tyrosine kinase is the closest homologue.
ALK is a 1620 amino acid transmembrane protein, which has
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an extracellular domain with an N-terminal signal peptide,
two MAM motifs (meprin, A5 protein, and receptor protein
tyrosine phosphatase mu), a low-density lipoprotein class A
motif, and a large glycine-rich region putative ligand binding
site. It also contains a short transmembrane domain and an
intracellular domain with a juxtamembranous segment with a
binding site for insulin receptor substrate-1, a kinase domain
with three tyrosine-containing motif (YxxxYY: tyrosines
1278, 1282, and 1283 within the activation loop) and a
C-terminus with binding sites for Src homology-2 and phos-
pholipase C-. Activation of ALK by binding of ligand leads
to dimerization, autophosphorylation, and signaling through
the RAS-ERK, JAK3-STAT3, and PI3-K/Akt pathways,
which lead to effects on cell proliferation, survival, migra-
tion, and alterations in cytoskeletal rearrangement.14
The normal physiological function of ALK in humans is
poorly understood. Drosophila melanogaster ALK (dALK)15
and its ligand Jeb (jelly belly)16 are important for the formation
of the visceral musculature of the gut17,18 and for the assem-
bly of the neuronal circuitry in the visual system.19 No
mammalian counterpart to Drosophila Jeb has been identi-
fied. Putative mammalian ligands are the heparin-binding
proteins pleiotrophin20 and midkine.21 Mammalian ALK is
expressed in the nervous system during embryogenesis and at
reduced levels after birth. Immunohistochemical studies in
adult human tissue reveal weak expression restricted to com-
ponents of the central nervous system.22 Interestingly, there
are no gross abnormalities in ALK knockout mice, with the
exception of subtle neurocognitive changes consistent with
alterations in hippocampal function.23 Several detailed re-
views of the basic biology of ALK have recently been
published.14,24,25
Echinoderm microtubule-associated protein-like 4
(EML4) is a 120 KDa cytoplasmic protein that is a human
homolog of echinoderm microtubule-associated protein, the
major microtubule binding protein in dividing sea urchin
eggs, and is essential for the formation of microtubules.26,27 It
is composed of a N-terminal basic region, a HELP domain,
and four WD repeats in the C-terminus.
ALK GENE REARRANGEMENTS IN CANCER
ALK was originally identified in 1994 in anaplastic
large-cell lymphomas (ALCL)28,29 as a component of a chi-
meric protein NPM-ALK created as a result of a translocation
between chromosomes 2 and 5 [t(2;5)(p23;q35)]. ALK rear-
rangements occur in 60 to 80% of ALCL, which are CD30
positive non-Hodgkin lymphomas (NHL) that present more
frequently in young patients and have a male preponderance.
ALCL accounts for about 40% of childhood NHL but only
5% of adult NHL.30,31 NPM-ALK is the most common fusion
in ALK-positive ALCL and consists of the N-terminal por-
tion of nucleophosmin (NPM) fused with the kinase domain
containing C-terminus of ALK. The fusion gene is readily
detected by reverse transcription-polymerase chain reaction
(RT-PCR) or fluorescent in situ hybridization (FISH) and can
also be detected by the ALK-1 (Dako, Carpinteria, CA)
antibody with typical nuclear and cytoplasmic localization. Nu-
merous other rearrangements involving ALK have been identi-
fied, including t(1;2)(q21;p23) (TPM3-ALK), inv(2)(p23q35)
(ATIC-ALK), t(2;3)(p23;q21) (TFG-ALK), t(2;17)(p23;q23)
(CLTC-ALK), t(2;19)(p23;q13.1) (TPM4-ALK), and t(X;2)
(q11–12;p23) (MSN-ALK).30,31
In addition to ALCL, ALK gene rearrangements have
also been described in 50% of inflammatory myofibroblastic
tumors32,33 and rare ALK-positive diffuse large B-cell lym-
phomas.34 Point mutations and amplifications of ALK have
been identified in sporadic and familial neuroblastomas.35–38
Proteomic studies have also reported on ALK proteins being
associated with esophageal squamous cell carcinoma.39,40
As has been observed in ALCL and IMT, with only rare
exceptions, ALK gene rearrangements in NSCLC contain the
complete tyrosine kinase domain of ALK (beginning from
exon 20, residues 1058–1620). In the gene rearrangement,
the promoter of the 5 partner gene controls the transcription
of the resulting fusion gene. The fusion partner in the trans-
lated fusion protein typically contains an oligomerization
domain that mediates constitutive dimerization and subse-
quent autophosphorylation and constitutive activation of the
ALK kinase in the absence of ligand. The partner protein also
determines cellular localization, which may affect the in-
duced phenotype in different fusions. In the case of EML4-
ALK, the location is cytoplasmic.9,41,42 This is distinct from
NPM-ALK where NPM drives nuclear and cytoplasmic ex-
pression, CTLC-ALK that has a granular cytoplasmic stain-
ing distribution,43and KIF5B-ALK that is associated with a
perinuclear distribution.8
METHODS OF DETECTION
ALK gene rearrangements or the resulting fusion pro-
teins may be detected in tumor specimens using immunohis-
tochemistry, RT-PCR of cDNA, and FISH. The ALK-1
antibody, which has proven useful in ALCL and inflamma-
tory myofibroblastic tumors, has not been as reliable in lung
carcinomas.42 Nevertheless, several strategies to improve the
accuracy of the immunohistochemistry ALK assays in lung
cancer including amplification of the signal with a tyramide
cascade44and intercalation of an antibody-enhanced polymer8
have recently been described.
RT-PCR of cDNA has been the most commonly ap-
plied screening strategy for ALK gene rearrangements in
archival tissue. Initially, only a few primer sets were tested,
but currently, a number of multiplex assays have been de-
signed to simultaneously capture all possible in-frame fusions
between EML4 and ALK in which the kinase domain of ALK
would be preserved.2,5,7 However, although different break-
points in EML4 or ALK may be detected with such tech-
niques, novel ALK fusion partners will not.
FISH has been performed with the ALK Dual Color
Break-Apart probe (Abbott Molecular, Des Plaines, IL)41,42,45
or “homebrew” reagents.46 The commercial break-apart
probe is comprised of a SpectrumOrange (red)-labeled 250 kb
probe to the 3 end of ALK with a SpectrumGreen (green)-
labeled 300 kb probe to the 5 end of ALK (Fig. 1). Because
the EML4 and ALK loci are mapped relatively close in 2p
(12.7 MB apart) and the chromosome inversion is frequently
associated with deletion around the ALK 5 breakpoint,7,46 the
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interpretation of a positive rearrangement (through the intro-
duction of a gap between the red and green probes) in
formalin-fixed, paraffin-embedded tissue sections can be
challenging. Internal and external controls must be used to
estimate whether, in each nucleus showing separated signals,
the distance between them is larger than would be expected
for stochastic separation of these signals. This distance is
estimated using the signal size as a reference, and therefore
analyses must be performed by experienced laboratory per-
sonnel. In such settings, break-apart FISH probes separated
by at least 8 MB can be readily detected with high sensitivity
and specificity in paraffin-embedded tissues.41 More sophis-
ticated strategies have also been proposed, such as a three-
color probe set with an additional fluorescent probe targeting
the deleted portion of chromosome 2 in ALK-rearranged
NSCLC44 or a dual-fusion color probe directed against both
fusion derivatives (Varella-Garcia, unpublished data). Al-
though none of these FISH probe sets can comprehensively
identify novel rearrangements, they can detect atypical pat-
terns of breakpoints in ALK, leading to additional analyses to
confirm the details of the gene rearrangements as needed.
CLINICAL/PATHOLOGIC FEATURES
The overall incidence of ALK gene rearrangements in
NSCLC in the series reported to date is 3.8% (107 ALK
rearrangements in 2835 tested tumors—with a range from 0.4
to 13.4%—see Table 1).2,5,7–9,11,41,42,45–48 Most ALK gene
rearrangements have been found in adenocarcinomas, in
never or light smokers. Consequently, any differing propor-
tions reported in the different series have to be considered in
light of their underlying enrichment for factors such as
specific histologies or patients with no or light smoking
histories. Coexpression with EGFR or KRASmutations seems
to be extremely rare, suggesting that ALK is a distinct
oncogenic driver. Patients with ALK-positive NSCLC have
been reported as being younger than patients without the gene
rearrangement in some series.9,45 Shaw et al have described
TABLE 1. Frequency of ALK Gene Rearrangements in NSCLC
Author
Method of





NSCLC Tumors Tested Percentage
Soda et al.2 RT-PCR Japan 5 75 6.7
Rikova et al.11 RT-PCR China 4a 103 3.9
Shinmura et al.48 RT-PCR Japan 2 77 2.6
Perner et al.46 FISH Switzerland, USA 16 603 2.7
Inamura et al.47 RT-PCR Japan 5 200 2.5
Koivunen et al.7 FISH USA (138), Korea (167) 8 305 2.6
Takeuchi et al.5 RT-PCR Japan 11 253 4.3
Wong et al.9 RT-PCR China 13 266 4.9
Boland et al.41 IHC, FISH USA 6 335 1.9
Martelli et al.42b RT-PCR Italy, Spain 9 120 7.5
Rodig et al.44c IHC, FISH USA 1 227 0.4
Shaw et al.45d FISH USA 19 141 13.5
Takeuchi et al.8 IHC, RT-PCR Japan 8e 130 6.2
Total 107 2835 3.8
a Includes one tumor with TRG-ALK fusion.
b 542 patients who had testing by IHC only are not included.
c Patients in the original report that are described in another series45 are excluded.
d Patients tested were preselected for factors associated with EGFR mutation positivity, enriching the tested population for factors that included
adenocarcinomas and low/never smoking status.
e Includes one tumor with KIF5-ALK fusion.
NSCLC, non-small cell lung cancer; RT-PCR, reverse transcription-polymerase chain reaction; FISH, fluorescent in situ hybridization; IHC,
immunohistochemistry.
FIGURE 1. A, Chromosome 2 idiogram showing location
and design of the dual-color ALK break-apart fluorescence in
situ hybridization (FISH) probe that includes DNA contigs
adjacent to the ALK gene, the 3 contig is labeled with red
fluorochromes and the 5 is labeled with green fluoro-
chromes. B, Non-small cell lung cancer (NSCLC) specimen
showing fused red/green signals representing normal copies
of the ALK (yellow arrows) and single red and green signals
(red and green arrows) indicating that chromosomal break
occurred between the 3 and the 5 contigs.
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that ALK-positive patients typically do not derive benefit
from treatment with EGFR inhibitors but have similar re-
sponse rates to chemotherapy as patients who have EGFR
wild-type tumors. Histopathologic associations have been made
with acinar patterns47or solid patterns containing signet-ring
features.44,45 To date, the overall incidence in largely uns-
elected series conducted in Asian (4.2%, 54 of 1271) and
Western (3.4%, 54 of 15164) populations seems similar.
Whether there will be significant geographical or racial vari-
ation in the frequency of ALK gene rearrangements when
only more defined clinical populations, such as adenocarci-
nomas with no/light smoking history, and/or only those
known to be EGFR and KRAS wild type are considered
remains to be seen.
TARGETING ALK GENE REARRANGEMENTS IN
NSCLC
Significant effort has been directed toward the genera-
tion of therapeutically useful ALK inhibitors.49 In preclinical
studies, several ALK inhibitors have shown activity against
NPM-ALK and EML4-ALK–containing cell lines.2,4,7,50,51
TAE684, a small molecule ALK inhibitor, inhibited the
growth of, and induced apoptosis in, H3122—an EML4-
ALK–containing NSCLC cell line—in vitro and caused re-
gression of xenografts in vivo.7 Another small molecule
tyrosine kinase inhibitor PF02341066, originally developed
as an inhibitor of mesenchymal epithelial transition growth
factor (c-MET), was found to also be a very potent inhibitor
of ALK. PF02341066 inhibited ALK phosphorylation and
signal transduction with associated G1-S phase cell cycle
arrest and induction of apoptosis in NPM-ALK–positive
ALCL cells in vitro and in vivo.50 Preliminary results of the
phase I study of PF02341066 in an expanded cohort of
patients with NSCLC with ALK gene rearrangements (de-
tected by break-apart FISH probe) have recently been pre-
sented. In the first 29 evaluable patients treated at the recom-
mended dose of 250 mg twice daily, 17 of 29 patients (59%)
had partial responses and 24 of 29 (83%) had disease control
(partial response  stable disease).52 Based on these encour-
aging results, a randomized phase III trial comparing ALK
inhibition to standard second-line cytotoxic chemotherapy in
patients with ALK-positive NSCLC has now commenced.
CONCLUSION
Inversions in the short arm of chromosome 2 that result
in one of several ALK gene rearrangements occur in approx-
imately 4% of NSCLC and comprise a newly defined molec-
ular subtype of NSCLC. The most common fusion protein
resulting from the gene rearrangement is EML4-ALK. ALK
gene rearrangements seem to be more common in adenocar-
cinomas from never or light smokers whose tumors are wild
type for EGFR and KRAS. As is the case in other ALK driven
cancers, ALK gene rearrangements in NSCLC result in con-
stitutive ALK activity, which is important for both tumori-
genesis and tumor maintenance. Activity of the ALK inhib-
itor PF02341066 in a subset of patients with ALK-positive
NSCLC treated on a phase I clinical trial has provided proof
of concept that ALK gene rearrangements and their associated
fusion proteins are valid therapeutic targets in NSCLC. The
results of a phase III trial comparing ALK inhibition to
cytotoxic chemotherapy in patients with ALK-positive
NSCLC are awaited.
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